acalabrutinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
pharma · Advanced Solid Tumor · Acute Myeloid Leukemia or Myelodysplastic Syndromes · APRE
Aprea Therapeutics
Aprea Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
3805 Old Easton Rd, Doylestown, Pennsylvania 18902, US HQ
15 Employees
Public company Type
APRE · NYSE Ticker
Company details
- Status
- Public
- HQ
- 3805 Old Easton Rd, Doylestown, Pennsylvania 18902, US
- Employees
- 15
- Programs
- 15
- Drugs
- 5
- Patents
- 6
Aprea Therapeutics pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Aprea Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in Aprea Therapeutics's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
azacitidine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 3A inhibitor
-
Development asset linked to Aprea Therapeutics in public FDA and regional records.
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor